Dr Steven Horwitz speaks to ecancer at the 2019 ASH meeting in Orlando about the latest results from the dose-optimisation portion of the phase II PRIMO trial.
He explains the background of the study, which aims to determine the optimal regimen of duvelisib as a monotherapy for the treatment of relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL).
Dr Horwitz states that there was a difference between 25 milligrams and 75 milligrams twice daily dose, in which patients in the 25 milligrams cohort displaying early progression.
Moving forward into the expansion phase, he mentions that all patients will receive the 75 milligrams twice daily regimen to start with, followed by 25 milligrams twice daily to maintain disease control and to minimise potential toxicities.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.